Lung cancer — symptoms and survival in the modern era

Lung cancer is the third most common cancer in the UK and leading cause of cancer death — ~48,000 cases yearly. Smoking causes most cases — but never-smokers develop lung cancer too — often different biology with targetable mutations.

Survival improving — immunotherapy and molecular targeted drugs transformed advanced NSCLC — early detection still best cure chance.

Symptoms — see GP

NICE referral criteria include:

  • haemoptysis — any amount — urgent CXR
  • chest X-ray for ≥3 week cough in smokers/ex-smokers
  • persistent/recurrent chest infection
  • weight loss, chest pain, hoarseness
  • clubbing, supraclavicular lymph node

Advanced:

  • bone pain
  • brain metastases — headache, seizures
  • SVCO — facial swelling, distended veins
  • pleural effusion — breathlessness

Types

Non-small cell lung cancer (NSCLC) — ~85%

  • adenocarcinoma — outer lung, never-smokers common
  • squamous cell carcinoma — central, smoking-linked
  • large cell

Small cell lung cancer (SCLC) — ~15%

  • rapid growth, early spread
  • chemoradiotherapy sensitive — limited vs extensive stage
  • prophylactic cranial irradiation selected limited stage

Diagnosis pathway

  1. Chest X-ray
  2. CT thorax — staging scan
  3. Biopsy — histology mandatory
  4. Molecular profiling — EGFR, ALK, ROS1, BRAF, PD-L1, KRAS
  5. PET-CT — metastasis search
  6. MDT — treatment plan

Treatment overview

Early NSCLC:

  • lobectomy — video-assisted thoracoscopic (VATS)
  • stereotactic ablative radiotherapy (SABR) — inoperable early

Locally advanced:

  • chemoradiotherapy
  • immunotherapy consolidation — durvalumab post-chemorRT

Advanced/metastatic NSCLC:

  • pembrolizumab monotherapy if PD-L1 high
  • chemo-immunotherapy combinations
  • osimertinib — EGFR mutation
  • alectinib — ALK
  • supportive care — breathlessness clinics

SCLC:

  • platinum-etoposide — extensive stage + atezolizumab/durvalumab

Prevention

  • stop smoking — risk falls but never to never-smoker level fully
  • avoid asbestos — occupational
  • radon — home testing high-risk areas

Lung cancer vs COPD

Both cause breathlessness and cough — new haemoptysis or weight loss — cancer until excluded — see COPD for chronic airflow limitation distinction.

3-week cough + smoking history — CXR same week — not repeat antibiotics alone.

Common questions about lung cancer

What are the early signs of lung cancer?
Persistent cough — new or changed — over 3 weeks, coughing blood, breathlessness, chest or shoulder pain, repeated chest infections, fatigue, weight loss, loss of appetite, hoarse voice, finger clubbing. Early stage may have no symptoms — reason screening pilots exist for high-risk groups.
Can non-smokers get lung cancer?
Yes — roughly 10 to 15% of cases — often adenocarcinoma in outer lung. Radon gas, occupational asbestos exposure, air pollution, and genetic factors contribute. Never assume immunity because you never smoked.
How is lung cancer diagnosed?
Chest X-ray first — CT chest with contrast if suspicious. PET-CT for staging. Biopsy — bronchoscopy, CT-guided needle, or EBUS for lymph nodes — confirms histology and molecular testing (EGFR, ALK, PD-L1). Staging determines treatment — I to IV.
Is lung cancer curable?
Stage I to II NSCLC — surgery or stereotactic radiotherapy can cure selected patients. Advanced stage — not usually curable but immunotherapy (pembrolizumab) and targeted drugs (osimertinib for EGFR) extend survival significantly compared to chemotherapy alone. Small cell — chemoradiotherapy sensitive but often relapses.
Should I get screened for lung cancer?
If invited to NHS Targeted Lung Health Check (current or ex-smokers 55–74 in pilot areas) — attend. No universal UK screening yet outside programmes. Discuss with GP if high risk — heavy smoking history, asbestos exposure.

Sources

How we reviewed this page

Medically reviewed by the HealthAnswers UK doctor review panel

First published
Medically reviewed
Next review due
or sooner if NHS or NICE guidance changes

Written by HealthAnswers editorial team. Published by HealthAnswers (Elite Digital AI Solutions Ltd). How we review content · Report a problem with this page